Kane Biotech Inc. (CVE:KNE – Get Free Report) shares fell 16.7% on Monday . The stock traded as low as C$0.02 and last traded at C$0.03. Approximately 327,000 shares traded hands during trading, an increase of 81% from the average session volume of 180,592 shares. The stock had previously closed at C$0.03.
Kane Biotech Price Performance
The stock has a market capitalization of C$5.13 million, a price-to-earnings ratio of -2.50 and a beta of 1.06. The business’s fifty day moving average price is C$0.03 and its 200-day moving average price is C$0.03. The company has a debt-to-equity ratio of -135.17, a current ratio of 0.45 and a quick ratio of 0.39.
Kane Biotech Company Profile
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.
Read More
- Five stocks we like better than Kane Biotech
- Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term Investors
- Doug Casey Calls AI a Super Bubble, Bets on Energy, Gold Miners and Grains
- This Edge AI Stock Just Got a Huge Vote of Confidence From Wall Street
- AI Is Selling Off, But These 5 Stocks Could Benefit Next
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
